CN114650821A - 口腔崩解片剂 - Google Patents

口腔崩解片剂 Download PDF

Info

Publication number
CN114650821A
CN114650821A CN202080078075.5A CN202080078075A CN114650821A CN 114650821 A CN114650821 A CN 114650821A CN 202080078075 A CN202080078075 A CN 202080078075A CN 114650821 A CN114650821 A CN 114650821A
Authority
CN
China
Prior art keywords
disorder
orally disintegrating
lubricant
disintegrating tablet
mannitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080078075.5A
Other languages
English (en)
Chinese (zh)
Inventor
剑持卓
山崎浩之
冈庆一
古关美香
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of CN114650821A publication Critical patent/CN114650821A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080078075.5A 2019-11-11 2020-11-11 口腔崩解片剂 Pending CN114650821A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPPCT/JP2019/044118 2019-11-11
PCT/JP2019/044118 WO2021095092A1 (ja) 2019-11-11 2019-11-11 口腔内崩壊錠
PCT/JP2020/042114 WO2021095779A1 (ja) 2019-11-11 2020-11-11 口腔内崩壊錠

Publications (1)

Publication Number Publication Date
CN114650821A true CN114650821A (zh) 2022-06-21

Family

ID=75911893

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080078075.5A Pending CN114650821A (zh) 2019-11-11 2020-11-11 口腔崩解片剂

Country Status (9)

Country Link
US (1) US20220387423A1 (https=)
EP (1) EP4059502A4 (https=)
JP (3) JP7395607B2 (https=)
CN (1) CN114650821A (https=)
AU (1) AU2020384456B2 (https=)
CA (1) CA3161119A1 (https=)
PH (1) PH12022551117A1 (https=)
TW (1) TWI873221B (https=)
WO (2) WO2021095092A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021095092A1 (ja) * 2019-11-11 2021-05-20 大塚製薬株式会社 口腔内崩壊錠
EP4574134A1 (en) * 2023-12-22 2025-06-25 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A tablet comprising brexpiprazole

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1913876A (zh) * 2003-12-09 2007-02-14 大日本住友制药株式会社 含药物的颗粒和包含这种颗粒的固体制剂
US20150110880A1 (en) * 2012-04-24 2015-04-23 Daiichi Sankyo Company, Limited Orally disintegrating tablet and production process therefor
CN106994119A (zh) * 2016-01-22 2017-08-01 浙江华海药业股份有限公司 含有依匹哌唑或其盐的口腔崩解片及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010001106A1 (en) * 1996-04-16 2001-05-10 Tomohiro Yoshinari D-mannitol and its preparation
JP4358117B2 (ja) * 2001-03-06 2009-11-04 協和発酵キリン株式会社 口腔内速崩壊錠
JP3996626B2 (ja) * 2004-06-22 2007-10-24 塩野義製薬株式会社 口腔内速崩壊錠
JP5004236B2 (ja) * 2005-02-09 2012-08-22 キッセイ薬品工業株式会社 口腔内崩壊錠
BRPI0808889A2 (pt) * 2007-03-13 2014-11-11 Dainippon Sumitomo Pharma Co Comprimido desintegrante oral
US8431618B2 (en) * 2008-03-31 2013-04-30 Asahi Kasei Chemicals Corporation Processed starch powder with excellent disintegration properties and manufacturing method thereof
CN102119034B (zh) * 2008-06-13 2013-05-22 大日本住友制药株式会社 在口腔中快速崩解的片剂和制备其的方法
WO2010021300A1 (ja) * 2008-08-18 2010-02-25 三菱商事フードテック株式会社 新規マンニトール打錠用賦形剤
JP5337430B2 (ja) * 2008-08-26 2013-11-06 高田製薬株式会社 口腔内速崩壊錠
JP5466880B2 (ja) * 2009-05-20 2014-04-09 京都薬品工業株式会社 口腔内崩壊錠
JP5733930B2 (ja) * 2009-09-09 2015-06-10 武田薬品工業株式会社 固形製剤
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
JP5897196B1 (ja) * 2015-10-05 2016-03-30 大同化成工業株式会社 糖又は糖アルコール、膨潤型結合剤、崩壊剤及び高吸収性賦形剤を含む複合化造粒物及びその製造方法
CN105412036A (zh) * 2015-12-24 2016-03-23 北京康立生医药技术开发有限公司 依匹哌唑口腔崩解片
JP6201017B2 (ja) * 2016-08-04 2017-09-20 佐藤製薬株式会社 硬度及び崩壊性に優れた口腔内崩壊錠の製造方法及び該製造方法により製造される口腔内崩壊錠
WO2021095092A1 (ja) 2019-11-11 2021-05-20 大塚製薬株式会社 口腔内崩壊錠

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1913876A (zh) * 2003-12-09 2007-02-14 大日本住友制药株式会社 含药物的颗粒和包含这种颗粒的固体制剂
US20150110880A1 (en) * 2012-04-24 2015-04-23 Daiichi Sankyo Company, Limited Orally disintegrating tablet and production process therefor
CN106994119A (zh) * 2016-01-22 2017-08-01 浙江华海药业股份有限公司 含有依匹哌唑或其盐的口腔崩解片及其制备方法

Also Published As

Publication number Publication date
WO2021095779A1 (ja) 2021-05-20
TWI873221B (zh) 2025-02-21
TW202128167A (zh) 2021-08-01
EP4059502A4 (en) 2023-12-13
PH12022551117A1 (en) 2023-08-23
CA3161119A1 (en) 2021-05-20
JP7395607B2 (ja) 2023-12-11
JP2024026205A (ja) 2024-02-28
WO2021095092A1 (ja) 2021-05-20
AU2020384456B2 (en) 2026-03-12
AU2020384456A1 (en) 2022-06-09
JP7676510B2 (ja) 2025-05-14
EP4059502A1 (en) 2022-09-21
JP2025118718A (ja) 2025-08-13
US20220387423A1 (en) 2022-12-08
JPWO2021095779A1 (https=) 2021-05-20

Similar Documents

Publication Publication Date Title
TWI634908B (zh) 包含有７－［４－（４－苯并［ｂ］噻吩－４－基－哌－１－基）丁氧基］－１Ｈ－喹啉－２－酮或其鹽之錠劑
CN102048734B (zh) 药物组合物
JP2025118718A (ja) 口腔内崩壊錠
JP2011006446A (ja) アトルバスタチン経口投与用粒子状医薬組成物
WO2019121849A1 (en) Pharmaceutical tablet composition comprising brexpiprazole
TW201336499A (zh) 經口用醫藥組合物
TWI794214B (zh) 包含5-氯-n4-[2-(二甲基磷醯基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺之醫藥調配物
TW201507734A (zh) 口腔貼附劑
JP7486258B2 (ja) 口腔内崩壊錠用顆粒、その製造方法および口腔内崩壊錠
WO2011049191A1 (ja) 経口投与用医薬組成物
HK40066890A (zh) 口腔崩解片剂
JPWO2017047586A1 (ja) 錠剤
HK40071352A (en) Orally disintegrating tablet
EA051121B1 (ru) Перорально распадающаяся таблетка
JP6676816B1 (ja) Ｌ−システイン配合ビタミンｃ高含有圧縮成形製剤
CN105555316B (zh) 通过二阶段的湿式制粒工序制备的崩解性颗粒组合物及含有该组合物的口腔内崩解片剂
JP6296829B2 (ja) ヒアルロン酸を含有する造粒物、該造粒物を用いて製造される錠剤及び膨潤抑制方法
JP6296828B2 (ja) ヒアルロン酸を含有する造粒物、該造粒物を用いて製造される錠剤及び膨潤抑制方法
JP6668666B2 (ja) イルベサルタンを含有する医薬組成物及びその製造方法
TW201740947A (zh) 含有阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）之經口固態製劑，及含有阿立哌唑之經口固態製劑的製造方法
JP2013245169A (ja) 医薬錠剤およびその製造方法
TW202014180A (zh) 含有希樂葆（Ｃｅｌｅｃｏｘｉｂ）的固體製劑及其製造方法
CN106535916A (zh) 片剂型速释性制剂、片剂用组合物及片剂型速释性制剂的制造方法
CN110582272A (zh) 含有贝西福韦酯或其药剂学上容许的盐的颗粒、包含此颗粒的药剂学组成物及其制备方法
TW201422224A (zh) 含有達泊西汀游離鹼的口腔用組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40066890

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination